vol 13, No.1 (2026)
The Masked Threat of Pre-Core Mutants in Pregnancy: High Viral Replication Despite HBeAg Negativity in an Algerian Cohort ( http://doi.org/10.65613/742338)
2026
Abstract
Background: Vertical transmission of Hepatitis B virus (HBV) remains the primary driver of chronic infection. Accurate assessment of maternal viral replication and timely prenatal screening are essential to prevent perinatal spread. This study investigated HBsAg seroprevalence, maternal clinico-biological profiles, transmission risk factors, and gestational screening timelines in pregnant women in Eastern Algeria.
Methods: A two-year retrospective cohort study (January 2024–December 2025) was conducted at the University Hospital Center Dr. Benbadis of Constantine, Algeria. Clinical, serological, molecular (quantitative real-time PCR), and biochemical parameters were collected from confirmed HBsAg-positive pregnant women and analyzed using SPSS v21.
Results: Among 10,135 pregnant women screened, 50 were confirmed HBsAg-positive (period prevalence: 0.49%). Mean maternal age was 32.5 years (54% aged 30–39 years), and 52% were multigravida. Primary exposure risk factors included invasive dental care (52%), prior surgery (26%), traditional hijama (18%), and blood transfusion (14%). Screening timing was critically delayed: 48% of cases were screened in the third trimester (27–40 weeks) and 8% at delivery. Serologically, 100% were total anti-HBc-positive, 32% HBeAg-positive, and 68% anti-HBe-positive. HBV DNA was quantified in 56% (n=28); among them, 20% of the total cohort exhibited high viremia (2 × 10⁴ to 2 × 10⁸ IU/mL) requiring antiviral prophylaxis, which was initiated with Tenofovir in 14%. Hepatic transaminases were normal in 82% and prothrombin time was preserved in 68% of patients.
Conclusion: Chronic HBV carriage in pregnant women in this cohort is characterized by a strong predominance of HBeAg-negative profiles yet high active viral replication driven by regional pre-core mutants. Relying solely on HBeAg screening is inadequate to stratify transmission risk. Late third-trimester diagnosis severely limits the therapeutic window for maternal antiviral prophylaxis. Universal first-trimester screening and routine access to quantitative HBV PCR are urgently required to eliminate vertical transmission.
Full Text
References
[1] World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis b infection, 2015.
[2] World Gastroenterology Organisation (WGO). Practice Guideline: Hepatitis B, 2016.
[3] World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy, 2020.
[4] World Health Organization. Hepatitis B Key Facts, 2024.
[5] Vidal France. Pregnancy and Hepatitis B Management Guidelines, 2025.
[6] EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017.
[7] Bouzid D, Brahimi M, Bouzid S, Benhassine L, Bouzid K. Prevalence of chronic hepatitis B and delta in northern Algeria. Pathologie Biologie, 2021.
[8] Tebbal S, Bouguermouh A, Belabbes H et al. Enquête nationale séroépidémiologique de l’AgHBs en Algérie. (IPA, INSP, OMS 1998); Communication orale. Alger 1998.
[9] Bourouiba A. Seroepidemiology of hepatitis B in Annaba among pregnant women. Sante Maghreb, 2004.
[10] Boumansour N, Midoun N, Mallem L, Hakem S. Epidemiological profile of hepatitis B in western Algeria, 2010–2012. Rev Epidemiol Sante Publique, 2016.
[11] Sbiti M, Khalki H, Benbella I, Louzi L. Sero-prevalence of HBsAg in pregnant women in central Morocco. Pan Afr Med J, 2016.
[12] Arfaoui D, Fkih M, Hafsa AE, Kaabia N, Azzouz M. Viral hepatitis B and pregnancy. Tunis Med, 2010.
[13] Lahlali M, Abid H, Lamine A, Lahmidani N, Yousfi ME, Benajah D, et al. epidémiologie des hépatites virales dans le Grand Maghreb epidemiology of viral hepatitis in the Maghreb. Tunis Med. 2018;96.
[15] Alassan KS, Imorou RS, Sonombiti H, Salifou K, Ouendo EM. Sero-prevalence and associated factors of viral hepatitis B among gestating women in Parakou, Benin. Pan Afr Med J, 2019.
[16] De San Feliciano L. La prévalence du dépistage du virus de l'Hépatite B chez la femme enceinte au Centre Hospitalier Universitaire de Grenoble en 2010. Mémoire de l'École de Sages-Femmes de Grenoble, Université Joseph Fourier, 2012.
[17] Stroffolini T, Bianco E, Szklo A, Bernacchia R, Bove C, Colucci M, et al. Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy. Vaccine. 7 mars 2003;21(11):1246‑9.
[18] Fomulu NJ, Morfaw FL, Torimiro JN, Nana P, Koh MV, William T. Prevalence, correlates and pattern of Hepatitis B among antenatal clinic attenders in Yaounde-Cameroon: is perinatal transmission of HBV neglected in Cameroon? BMC Pregnancy Childbirth. déc 2013;13(1):158.
[19] Adekanle O, Ijarotimi O, Obasi E, Anthony-Nwojo N, Ndububa D. Five-year study of liver disease admissions in Southwest Nigeria. Niger J Gastroenterol Hepatol, 2020.
[20] Safer L, Ben Chaabene N, Melki W, Saffar H. Epidemiology of viral hepatitis in Tunisia. Rev Epidemiol Sante Publique, 2006.
[21] Wang YC, Yang SS, Su CW, Wang YJ, Lee KC, Huo TI, et al. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world analysis. Sci Rep, 2016.
[22] Azzam A, Khaled H, El-kayal ES, Gad FA, Omar S. Prevalence of occult hepatitis B virus infection in Egypt: a systematic review with meta-analysis. J Egypt Public Health Assoc. 26 juill 2023;98(1):13.
[23] El Bouazzaoui L, El Fakir S, El Kettani A, El Mzibri M, Benjelloun MC. Prévalence du virus de l’hépatite B chez les femmes enceintes dans la région de Marrakech (Maroc). Revue Marocaine de Santé Publique. 2022;3(2):45‑52.
[24] Mamadou Bobo Diallo, Celestin GUILAVOGUI, Oumar Diouhé BAH, Kanimba BAH, Aboubacar, Kadiatou CAMARA, et al. Rev Mali Infect Microbiol. 2023;18(1):5.
[25] PREVALENCE ET PRISE EN CHARGE DE L’ANTIGÈNE HBs POSITIF CHEZ LES GESTANTES ET ACCOUCHEES À L’HÔPITAL FOUSSEYNI DAOU DE KAYES. [MALI]: Université des Sciences des Techniques et des Technologies de Bamako; 2023.
[26] Ramamurthy S, Suresh R, Ganesan P. Serological profile of chronic hepatitis B carriers – A tertiary care experience. Asian J Med Sci. 1 août 2023;14(8):121‑7.
[27] Guardiola Arévalo A, Gómez Rodríguez R, Romero Gutiérrez M, Gómez Moreno AZ, García Vela A, Sánchez Simón R, et al. Characteristics and course of chronic hepatitis B e antigen-negative infection. Gastroenterol Hepatol Engl Ed. févr 2017;40(2):59‑69.
[28] Khelifa F, Thibault V. Characteristics of chronic hepatitis B virus strains in Northeastern Algeria. Pathol Biol, 2009.
[29] Asgeir Johannessen, Bitsatab Mekasha, Hailemichael Desalegn, Hanna Aberra, Kathrine Stene-Johansen. Mother-to-Child Transmission of Hepatitis B Virus in Ethiopia. 2021;10.
[30] Hannachi N, Bahri O, Mhalla S, Marzouk M, Sadraoui A, Belguith A, et al. Viral hepatitis B among Tunisian pregnant women: risk factors and value of viral replication study in HBeAg-negative cases. Pathol Biol, 2009.
[31] Cheung KW, Seto MTY, So PL, Wong D, Mak ASL, Lau WL, et al. Optimal timing of hepatitis B virus DNA quantification during pregnancy. Acta Obstet Gynecol Scand, 2019.
[32] Chaabouni H, Rekik K, Chakroun A, Hammami F, Marrakchi C. Particularities of hepatitis B in pregnant women: a study of 107 cases. Tunis Med, 2018.
[33] Sun X, Wang C, Wang B, Yang X, Xu H, Shen M, et al. Efficacy of nucleos(t)ide analogues in blocking mother-to-child transmission of hepatitis B. Infect Dis Obstet Gynecol, 2020.
[34] Liu J, et al. Characteristics of liver function biochemical markers and transaminase elevations among HBsAg-positive pregnant women. Chin Med J / World J Gastroenterol. 2021;Volume:[Pages].
[2] World Gastroenterology Organisation (WGO). Practice Guideline: Hepatitis B, 2016.
[3] World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy, 2020.
[4] World Health Organization. Hepatitis B Key Facts, 2024.
[5] Vidal France. Pregnancy and Hepatitis B Management Guidelines, 2025.
[6] EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017.
[7] Bouzid D, Brahimi M, Bouzid S, Benhassine L, Bouzid K. Prevalence of chronic hepatitis B and delta in northern Algeria. Pathologie Biologie, 2021.
[8] Tebbal S, Bouguermouh A, Belabbes H et al. Enquête nationale séroépidémiologique de l’AgHBs en Algérie. (IPA, INSP, OMS 1998); Communication orale. Alger 1998.
[9] Bourouiba A. Seroepidemiology of hepatitis B in Annaba among pregnant women. Sante Maghreb, 2004.
[10] Boumansour N, Midoun N, Mallem L, Hakem S. Epidemiological profile of hepatitis B in western Algeria, 2010–2012. Rev Epidemiol Sante Publique, 2016.
[11] Sbiti M, Khalki H, Benbella I, Louzi L. Sero-prevalence of HBsAg in pregnant women in central Morocco. Pan Afr Med J, 2016.
[12] Arfaoui D, Fkih M, Hafsa AE, Kaabia N, Azzouz M. Viral hepatitis B and pregnancy. Tunis Med, 2010.
[13] Lahlali M, Abid H, Lamine A, Lahmidani N, Yousfi ME, Benajah D, et al. epidémiologie des hépatites virales dans le Grand Maghreb epidemiology of viral hepatitis in the Maghreb. Tunis Med. 2018;96.
[15] Alassan KS, Imorou RS, Sonombiti H, Salifou K, Ouendo EM. Sero-prevalence and associated factors of viral hepatitis B among gestating women in Parakou, Benin. Pan Afr Med J, 2019.
[16] De San Feliciano L. La prévalence du dépistage du virus de l'Hépatite B chez la femme enceinte au Centre Hospitalier Universitaire de Grenoble en 2010. Mémoire de l'École de Sages-Femmes de Grenoble, Université Joseph Fourier, 2012.
[17] Stroffolini T, Bianco E, Szklo A, Bernacchia R, Bove C, Colucci M, et al. Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy. Vaccine. 7 mars 2003;21(11):1246‑9.
[18] Fomulu NJ, Morfaw FL, Torimiro JN, Nana P, Koh MV, William T. Prevalence, correlates and pattern of Hepatitis B among antenatal clinic attenders in Yaounde-Cameroon: is perinatal transmission of HBV neglected in Cameroon? BMC Pregnancy Childbirth. déc 2013;13(1):158.
[19] Adekanle O, Ijarotimi O, Obasi E, Anthony-Nwojo N, Ndububa D. Five-year study of liver disease admissions in Southwest Nigeria. Niger J Gastroenterol Hepatol, 2020.
[20] Safer L, Ben Chaabene N, Melki W, Saffar H. Epidemiology of viral hepatitis in Tunisia. Rev Epidemiol Sante Publique, 2006.
[21] Wang YC, Yang SS, Su CW, Wang YJ, Lee KC, Huo TI, et al. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world analysis. Sci Rep, 2016.
[22] Azzam A, Khaled H, El-kayal ES, Gad FA, Omar S. Prevalence of occult hepatitis B virus infection in Egypt: a systematic review with meta-analysis. J Egypt Public Health Assoc. 26 juill 2023;98(1):13.
[23] El Bouazzaoui L, El Fakir S, El Kettani A, El Mzibri M, Benjelloun MC. Prévalence du virus de l’hépatite B chez les femmes enceintes dans la région de Marrakech (Maroc). Revue Marocaine de Santé Publique. 2022;3(2):45‑52.
[24] Mamadou Bobo Diallo, Celestin GUILAVOGUI, Oumar Diouhé BAH, Kanimba BAH, Aboubacar, Kadiatou CAMARA, et al. Rev Mali Infect Microbiol. 2023;18(1):5.
[25] PREVALENCE ET PRISE EN CHARGE DE L’ANTIGÈNE HBs POSITIF CHEZ LES GESTANTES ET ACCOUCHEES À L’HÔPITAL FOUSSEYNI DAOU DE KAYES. [MALI]: Université des Sciences des Techniques et des Technologies de Bamako; 2023.
[26] Ramamurthy S, Suresh R, Ganesan P. Serological profile of chronic hepatitis B carriers – A tertiary care experience. Asian J Med Sci. 1 août 2023;14(8):121‑7.
[27] Guardiola Arévalo A, Gómez Rodríguez R, Romero Gutiérrez M, Gómez Moreno AZ, García Vela A, Sánchez Simón R, et al. Characteristics and course of chronic hepatitis B e antigen-negative infection. Gastroenterol Hepatol Engl Ed. févr 2017;40(2):59‑69.
[28] Khelifa F, Thibault V. Characteristics of chronic hepatitis B virus strains in Northeastern Algeria. Pathol Biol, 2009.
[29] Asgeir Johannessen, Bitsatab Mekasha, Hailemichael Desalegn, Hanna Aberra, Kathrine Stene-Johansen. Mother-to-Child Transmission of Hepatitis B Virus in Ethiopia. 2021;10.
[30] Hannachi N, Bahri O, Mhalla S, Marzouk M, Sadraoui A, Belguith A, et al. Viral hepatitis B among Tunisian pregnant women: risk factors and value of viral replication study in HBeAg-negative cases. Pathol Biol, 2009.
[31] Cheung KW, Seto MTY, So PL, Wong D, Mak ASL, Lau WL, et al. Optimal timing of hepatitis B virus DNA quantification during pregnancy. Acta Obstet Gynecol Scand, 2019.
[32] Chaabouni H, Rekik K, Chakroun A, Hammami F, Marrakchi C. Particularities of hepatitis B in pregnant women: a study of 107 cases. Tunis Med, 2018.
[33] Sun X, Wang C, Wang B, Yang X, Xu H, Shen M, et al. Efficacy of nucleos(t)ide analogues in blocking mother-to-child transmission of hepatitis B. Infect Dis Obstet Gynecol, 2020.
[34] Liu J, et al. Characteristics of liver function biochemical markers and transaminase elevations among HBsAg-positive pregnant women. Chin Med J / World J Gastroenterol. 2021;Volume:[Pages].
Editor-in-Chief
Professor Roy G Beran
University of New South Wales
Email:
roy.g.beran@thomsonreuters-au.com
roy.g.beran@thomsonreuters-au.com
Contact Cell:
+61-480-00-857-3
+61-480-00-857-3
Publication Frequency
Monthly
Article Processing Charges (APCs)
US $3000
Indexing